NO20031642L - Humaniserte anti-LT-ß-R-antistoff - Google Patents

Humaniserte anti-LT-ß-R-antistoff

Info

Publication number
NO20031642L
NO20031642L NO20031642A NO20031642A NO20031642L NO 20031642 L NO20031642 L NO 20031642L NO 20031642 A NO20031642 A NO 20031642A NO 20031642 A NO20031642 A NO 20031642A NO 20031642 L NO20031642 L NO 20031642L
Authority
NO
Norway
Prior art keywords
antibody
humanized anti
humanized
Prior art date
Application number
NO20031642A
Other languages
English (en)
Norwegian (no)
Other versions
NO20031642D0 (no
Inventor
Ellen A Garber
Paul Lyne
Jose William Saldanha
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of NO20031642D0 publication Critical patent/NO20031642D0/no
Publication of NO20031642L publication Critical patent/NO20031642L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20031642A 2000-10-13 2003-04-10 Humaniserte anti-LT-ß-R-antistoff NO20031642L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24028500P 2000-10-13 2000-10-13
US27528901P 2001-03-13 2001-03-13
US29998701P 2001-06-21 2001-06-21
PCT/US2001/032140 WO2002030986A2 (en) 2000-10-13 2001-10-12 HUMANIZED ANTI-LT-β-R ANTIBODIES

Publications (2)

Publication Number Publication Date
NO20031642D0 NO20031642D0 (no) 2003-04-10
NO20031642L true NO20031642L (no) 2003-06-13

Family

ID=27399340

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031642A NO20031642L (no) 2000-10-13 2003-04-10 Humaniserte anti-LT-ß-R-antistoff

Country Status (25)

Country Link
US (2) US7429644B2 (zh)
EP (1) EP1326897A2 (zh)
JP (1) JP2004532608A (zh)
KR (1) KR20030041164A (zh)
CN (1) CN1547590A (zh)
AR (1) AR035352A1 (zh)
AU (2) AU2002211747B2 (zh)
BG (1) BG107802A (zh)
BR (1) BR0114646A (zh)
CA (1) CA2425809A1 (zh)
CZ (1) CZ20031307A3 (zh)
EA (1) EA006945B1 (zh)
EE (1) EE200300179A (zh)
GE (1) GEP20063752B (zh)
HU (1) HUP0302573A2 (zh)
IL (1) IL155340A0 (zh)
IS (1) IS6779A (zh)
MX (1) MXPA03003144A (zh)
NO (1) NO20031642L (zh)
NZ (1) NZ525793A (zh)
PL (1) PL366307A1 (zh)
SK (1) SK5672003A3 (zh)
TR (2) TR200602095T2 (zh)
WO (1) WO2002030986A2 (zh)
YU (1) YU28503A (zh)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
NZ537965A (en) * 2002-07-01 2008-04-30 Biogen Idec Inc Humanized anti-lymphotoxin beta receptor antibodies
WO2004058191A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
CN1753692A (zh) * 2002-12-20 2006-03-29 比奥根艾迪克Ma公司 淋巴毒素β受体药剂与化疗剂的联合用药
EP1641827A2 (en) 2003-06-27 2006-04-05 Biogen Idec MA Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
EP1697415A1 (en) 2003-11-12 2006-09-06 Biogen Idec MA Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
CA2560742A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
US8153123B2 (en) * 2004-12-09 2012-04-10 La Jolla Institute For Allergy And Immunology Method for restoring dendritic cell populations
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
KR20180002911A (ko) 2005-11-04 2018-01-08 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
JP2007295524A (ja) * 2006-03-28 2007-11-08 Denso Corp 情報通信システム、施設側装置、ユーザ側装置、管理装置、車両側装置、施設側プログラム、ユーザ側プログラム、管理プログラム及び車両側プログラム
NZ572565A (en) * 2006-05-25 2011-04-29 Glaxo Group Ltd Modified humanised anti-interleukin-18 antibodies
EP2067041A2 (en) 2006-10-03 2009-06-10 Biogen Idec MA, Inc. Biomarkers and assays for the treatment of cancer
CL2007002926A1 (es) 2006-10-12 2008-05-16 Genentech Inc Anticuerpo antilinfotoxina alfa (lt-alfa); composicion con el anticuerpo; hibridoma pta-7538; acido nucleico codificante del anticuerpo; vector y celula huesped que comprenden el acido nucleico; metodo para inhibir la proliferacion celular activada p
CA2666934A1 (en) * 2006-10-20 2008-04-24 Biogen Idec Ma Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
KR20160092061A (ko) 2006-11-02 2016-08-03 제넨테크, 인크. 인간화 항-ｄ 인자 항체
US8003761B2 (en) * 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
WO2009000099A2 (en) 2007-06-25 2008-12-31 Esbatech Ag Methods of modifying antibodies, and modified antibodies with improved functional properties
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
US8846042B2 (en) 2011-05-16 2014-09-30 Fabion Pharmaceuticals, Inc. Multi-specific FAB fusion proteins and methods of use
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
CN107318267B (zh) 2013-08-12 2021-08-17 豪夫迈·罗氏有限公司 用于治疗补体相关的病症的组合物和方法
BR112016025312A2 (pt) 2014-05-01 2017-10-17 Genentech Inc variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem
SI3215528T1 (sl) 2014-11-06 2019-11-29 Hoffmann La Roche Variante regije Fc s spremenjeno vezavo FcRn in postopki uporabe
MX2018000548A (es) 2015-07-14 2018-09-26 Immunext Inc Anticuerpo anti-cd154 con características de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana.
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート
JP7034489B2 (ja) 2016-03-15 2022-03-14 アイタブメッド （エイチケイ） リミテッド 多重特異性Ｆａｂ融合タンパクおよびその使用
CN115087670A (zh) 2019-12-11 2022-09-20 西拉格国际有限责任公司 包含ltbr和edb结合结构域的多特异性结合分子及其用途
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
WO2022117572A2 (en) 2020-12-02 2022-06-09 Oncurious Nv An ltbr agonist in combination therapy against cancer
WO2023117834A1 (en) 2021-12-20 2023-06-29 F. Hoffmann-La Roche Ag Agonistic ltbr antibodies and bispecific antibodies comprising them
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023218320A1 (en) * 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994013808A2 (en) 1992-12-04 1994-06-23 Biogen, Inc. LYMPHOTOXIN-β, LYMPHOTOXIN-β COMPLEXES, PHARMACEUTICAL PREPARATIONS AND THERAPEUTIC USES THEREOF
EP0536299B1 (en) 1990-06-27 2001-06-06 Biogen, Inc. Surface complexed lymphotoxin
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU725351B2 (en) * 1995-01-26 2000-10-12 Biogen Idec Ma Inc. Lymphotoxin-alpha/beta complexes and anti-lymphotoxin-beta receptor antibodies as anti-tumor agents
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
BR9908214A (pt) 1998-01-30 2000-11-28 Biogen Inc Tratamento para linfomas foliculares utilizando inibidores da via da linfotoxina (lt)
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
NZ537965A (en) * 2002-07-01 2008-04-30 Biogen Idec Inc Humanized anti-lymphotoxin beta receptor antibodies
WO2004058191A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
CN1753692A (zh) * 2002-12-20 2006-03-29 比奥根艾迪克Ma公司 淋巴毒素β受体药剂与化疗剂的联合用药

Also Published As

Publication number Publication date
EE200300179A (et) 2003-08-15
NO20031642D0 (no) 2003-04-10
AU1174702A (en) 2002-04-22
TR200602095T2 (tr) 2007-02-21
CZ20031307A3 (cs) 2003-10-15
EP1326897A2 (en) 2003-07-16
US20040058394A1 (en) 2004-03-25
EA200300464A1 (ru) 2003-10-30
IS6779A (is) 2003-04-11
NZ525793A (en) 2008-04-30
YU28503A (sh) 2006-05-25
CN1547590A (zh) 2004-11-17
KR20030041164A (ko) 2003-05-23
JP2004532608A (ja) 2004-10-28
AR035352A1 (es) 2004-05-12
US20090092601A1 (en) 2009-04-09
EA006945B1 (ru) 2006-06-30
CA2425809A1 (en) 2002-04-18
GEP20063752B (en) 2006-02-27
WO2002030986A3 (en) 2003-03-13
IL155340A0 (en) 2003-11-23
BG107802A (bg) 2004-01-30
US7429644B2 (en) 2008-09-30
SK5672003A3 (en) 2003-10-07
TR200300478T2 (tr) 2004-10-21
PL366307A1 (en) 2005-01-24
MXPA03003144A (es) 2004-12-06
WO2002030986A2 (en) 2002-04-18
AU2002211747B2 (en) 2007-11-29
BR0114646A (pt) 2006-02-21
HUP0302573A2 (hu) 2003-10-28

Similar Documents

Publication Publication Date Title
NO20031642L (no) Humaniserte anti-LT-ß-R-antistoff
DE60222658D1 (de) Monoklonaler anti-cd-40-antikörper
IL156030A0 (en) Humanized antibodies
IS6982A (is) Mótefni gegn VLA-1
NO20044347L (no) Anti-alfavbeta6-antistoff
DK1501856T3 (da) Anti-HER2 antistofvarianter
DE50100900D1 (de) Fixierelement
DK1314437T3 (da) Stabiliserede antistofindeholdende præparater
DE60044829D1 (de) Chromenverbindung
DK1226127T3 (da) Substituerede phenylsulfamoylcarboxamider
DE60114153D1 (de) Substituierte arylpyrazine
AR028393A1 (es) Iminoazidas substituidas
DE10085449T1 (de) Fixiervorrichtung
NO20032338L (no) Tappekran
EE200300569A (et) CD44v6-spetsiifilised antikehad
DK1164375T3 (da) Assay til antitransglutaminaseantistoffer
AR028302A1 (es) Feniluracilos substituidos
ATE365721T1 (de) Substituierte benzoylcyclohexenone
DE60104562D1 (de) Bewegungsmechanismus
FI20011055A0 (fi) Heveiiniä sitovat monoklonaaliset vasta-aineet
ITPD20000192A0 (it) Anticorpi policlonali
DE60135621D1 (de) Fixiergerät
AR028262A1 (es) Anticuerpos especificos de fap-alfa humanos
DK1503799T3 (da) Immunogent, monoklonalt antistof
GB0029846D0 (en) Monoclonal antibody

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application